BioGaia has signed a non-exclusive agreement with Pharma Base SA for the rights
to sell BioGaia’s ProTectis Baby Drops in India. Pharma Base will cooperate with
a local distributor for the marketing and sales of the drops, which will be sold
under BioGaia’s own brand. The registration of the product will start 2014 and
the launch is planned to the beginning of 2015.
Pharma Base SA is a Swiss health company founded in 1996. Apart from the
headquarters in Switzerland the company has research and development facilities
as well as manufacturing plants in India and a sales office in New York. Pharma
Base concentrates its efforts on naturally occurring compounds, with glucosamine
being their most important ingredient.
Marketing of the BioGaia drops will be focused on the Mumbai region and in the
state of Maharashtra.
“India offers a monumental business potential and a huge opportunity for BioGaia
drops”, says Harish Parekh, Chairman & President of Pharma Base Group.
BioGaia ProTectis Baby Drops contain BioGaia’s patented and well-researched
probiotic strain Lactobacillus reuteri Protectis. Today the drops are sold in
around 60 countries.
“For a long time we have tried to find a suitable way to enter the large Indian
market. Through the agreement with Pharma Base we have access to a partner with
extensive experience in the Indian market and with a proven track record”, says
Peter Rothschild, President, BioGaia.
Latest press releases from BioGaia
2014-05-07 Annual General Meeting in BioGaia AB
2014-05-06 BioGaia AB: Interim report 1 January-31 March 2014
2014-04-07 Notice of Annual General Meeting in BioGaia AB
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 17 June 2014, 09:00 am
CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
